128 related articles for article (PubMed ID: 1450409)
1. Long-term engraftment of fresh human myeloma cells in SCID mice.
Feo-Zuppardi FJ; Taylor CW; Iwato K; Lopez MH; Grogan TM; Odeleye A; Hersh EM; Salmon SE
Blood; 1992 Dec; 80(11):2843-50. PubMed ID: 1450409
[TBL] [Abstract][Full Text] [Related]
2. The SCID mouse as a model for multiple myeloma.
Ahsmann EJ; van Tol MJ; Oudeman-Gruber J; Lokhorst H; Uytdehaag FG; Schuurman HJ; Bloem AC
Br J Haematol; 1995 Feb; 89(2):319-27. PubMed ID: 7873382
[TBL] [Abstract][Full Text] [Related]
3. The development of a model for the homing of multiple myeloma cells to human bone marrow.
Urashima M; Chen BP; Chen S; Pinkus GS; Bronson RT; Dedera DA; Hoshi Y; Teoh G; Ogata A; Treon SP; Chauhan D; Anderson KC
Blood; 1997 Jul; 90(2):754-65. PubMed ID: 9226176
[TBL] [Abstract][Full Text] [Related]
4. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
Pilarski LM; Hipperson G; Seeberger K; Pruski E; Coupland RW; Belch AR
Blood; 2000 Feb; 95(3):1056-65. PubMed ID: 10648422
[TBL] [Abstract][Full Text] [Related]
5. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice.
Tong AW; Huang YW; Zhang BQ; Netto G; Vitetta ES; Stone MJ
Anticancer Res; 1993; 13(3):593-7. PubMed ID: 8391243
[TBL] [Abstract][Full Text] [Related]
6. Demonstration of serum monoclonal immunoglobulin in a case of non-secretory myeloma by immunoisoelectric focusing.
Sheehan T; Sinclair D; Tansey P; O'Donnell JR
J Clin Pathol; 1985 Jul; 38(7):806-9. PubMed ID: 3926829
[TBL] [Abstract][Full Text] [Related]
7. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
8. An in vivo model of human multidrug-resistant multiple myeloma in SCID mice.
Bellamy WT; Odeleye A; Finley P; Huizenga B; Dalton WS; Weinstein RS; Hersh EM; Grogan TM
Am J Pathol; 1993 Mar; 142(3):691-7. PubMed ID: 8456932
[TBL] [Abstract][Full Text] [Related]
9. Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.
Huang SY; Tien HF; Su FH; Hsu SM
Am J Pathol; 2004 Feb; 164(2):747-56. PubMed ID: 14742278
[TBL] [Abstract][Full Text] [Related]
10. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host.
Yaccoby S; Epstein J
Blood; 1999 Nov; 94(10):3576-82. PubMed ID: 10552969
[TBL] [Abstract][Full Text] [Related]
11. Identification of intracellular immunoglobulin in extramedullary myeloma.
Halliday D; Davey FR; Call F; Marucci AA
Arch Pathol Lab Med; 1977 Oct; 101(10):522-5. PubMed ID: 410387
[TBL] [Abstract][Full Text] [Related]
12. Development of an in vivo model of human multiple myeloma bone disease.
Alsina M; Boyce B; Devlin RD; Anderson JL; Craig F; Mundy GR; Roodman GD
Blood; 1996 Feb; 87(4):1495-501. PubMed ID: 8608240
[TBL] [Abstract][Full Text] [Related]
13. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.
Yaccoby S; Barlogie B; Epstein J
Blood; 1998 Oct; 92(8):2908-13. PubMed ID: 9763577
[TBL] [Abstract][Full Text] [Related]
14. Distribution and engraftment patterns of human tonsillar mononuclear cells and immunoglobulin-secreting cells in mice with severe combined immunodeficiency: role of the Epstein-Barr virus.
Nadal D; Albini B; Chen CY; Schläpfer E; Bernstein JM; Ogra PL
Int Arch Allergy Appl Immunol; 1991; 95(4):341-51. PubMed ID: 1660036
[TBL] [Abstract][Full Text] [Related]
15. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.
Huang YW; Richardson JA; Tong AW; Zhang BQ; Stone MJ; Vitetta ES
Cancer Res; 1993 Mar; 53(6):1392-6. PubMed ID: 8443818
[TBL] [Abstract][Full Text] [Related]
16. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
[TBL] [Abstract][Full Text] [Related]
17. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor.
Tsunenari T; Koishihara Y; Nakamura A; Moriya M; Ohkawa H; Goto H; Shimazaki C; Nakagawa M; Ohsugi Y; Kishimoto T; Akamatsu K
Blood; 1997 Sep; 90(6):2437-44. PubMed ID: 9310495
[TBL] [Abstract][Full Text] [Related]
18. [A case of multiple myeloma with double M-protein peaks for IgG-kappa and IgA-kappa].
Tadao F; Hayashi M; Ichikawa K; Hirasawa Y; Ohtani H; Saito M; Hatimura K; Oshikawa T; Takayama M; Mori N
Rinsho Ketsueki; 1984 Oct; 25(10):1646-52. PubMed ID: 6441031
[No Abstract] [Full Text] [Related]
19. A clinically relevant SCID-hu in vivo model of human multiple myeloma.
Tassone P; Neri P; Carrasco DR; Burger R; Goldmacher VS; Fram R; Munshi V; Shammas MA; Catley L; Jacob GS; Venuta S; Anderson KC; Munshi NC
Blood; 2005 Jul; 106(2):713-6. PubMed ID: 15817674
[TBL] [Abstract][Full Text] [Related]
20. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
Pilarski LM; Belch AR
Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
